Excluder支架在不符合IFU的主动脉瘤颈解剖患者中的中期随访结果:GREAT注册研究
该研究为GREAT注册研究的回顾性亚分析,纳入3324例使用GORE EXCLUDER腹主动脉瘤支架的患者,其中411例(12.4%)存在挑战性瘤颈(不符合IFU)。结果显示挑战性瘤颈组5年全因死亡率和主动脉相关死亡率更高,Ia型内漏和再干预率也更高。
要点
- 不符合IFU的挑战性瘤颈患者5年全因死亡率和主动脉相关死亡率显著升高
- 挑战性瘤颈组Ia型内漏发生率和再干预需求均高于符合IFU组
- 不符合IFU的肾下腹主动脉腔内修复应仅在无替代方案时谨慎使用
核心结论
- 在不符合IFU的挑战性瘤颈患者中使用Excluder支架与更高的5年死亡率、Ia型内漏发生率和再干预需求相关。
- 建议对主动脉瘤颈解剖不符合IFU的病例应强烈考虑开窗支架或开放手术治疗。
- 不符合IFU的肾下腹主动脉腔内介入应仅在无替代方案时使用,并需精细的手术规划和干预。
研究设计与样本
- 该研究为全球血管内主动脉治疗注册研究(GREAT)的回顾性亚分析。
- 共纳入3324例使用GORE EXCLUDER腹主动脉瘤支架治疗的患者。
- 挑战性瘤颈定义为不符合IFU且主动脉瘤颈长度<15 mm和/或瘤颈角度>60°;411例(12.4%)为挑战性瘤颈,2913例(87.6%)为符合IFU。
主要发现
- 挑战性瘤颈组5年全因死亡率为36.2% vs. 27.5%(P=0.002),主动脉相关死亡率为3.8% vs. 1.1%(P=0.002),均显著更高。
- 挑战性瘤颈组Ia型内漏发生率为7% vs. 1.2%(P<0.001),再干预需求为13.3% vs. 9.7%(P<0.001),均更高。
- 多因素分析中,年龄增加与死亡时间缩短相关(HR 1.051,95%CI 1.039-1.062,P<0.0001),吸烟也与死亡风险增加相关(HR 1.329,95%CI 1.124-1.571,P=0.0009)。
- 腹主动脉瘤直径每增加1毫米,5年内死亡风险增加1.1%(P=0.0005)。
- 挑战性瘤颈组患者年龄更大(74.9岁 vs. 73.2岁,P≤0.0001),动脉瘤直径更大(61.2 mm vs. 56.4 mm,P<0.0001),近端瘤颈更短(18 mm vs. 30 mm,P<0.0001),肾下瘤颈角度更大(60.8° vs. 25.8°,P<0.0001)。
关键数值与推荐
- 挑战性瘤颈:不符合IFU且主动脉瘤颈长度<15 mm和/或瘤颈角度>60°。
- 5年全因死亡率:挑战性瘤颈组36.2% vs. 符合IFU组27.5%(P=0.002)。
- 5年主动脉相关死亡率:挑战性瘤颈组3.8% vs. 符合IFU组1.1%(P=0.002)。
- Ia型内漏发生率:挑战性瘤颈组7% vs. 符合IFU组1.2%(P<0.001)。
- 再干预需求:挑战性瘤颈组13.3% vs. 符合IFU组9.7%(P<0.001)。
临床怎么用
- 对于主动脉瘤颈解剖不符合IFU的患者,应优先考虑开窗支架或开放手术等替代治疗方案。
- 仅在无替代方案时方可对不符合IFU的肾下腹主动脉瘤行腔内修复,并需进行精细的术前规划和术中干预以改善预后。
- 对年龄较大、动脉瘤直径较大、近端瘤颈较短或角度较大的患者应加强术后随访监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The utilisation rate of endovascular aortic aneurysm repair has increased continuously over the past 2 decades. Endovascular aortic aneurysm repair is still performed frequently in patients with an unfavourable proximal seal zone, despite the associated late complications. PURPOSE: We aimed to evaluate the mid-term durability of the GORE® EXCLUDER® AAA Endoprosthesis, featuring the C3 delivery system, in patients with a proximal neck anatomy outside the instructions for use (IFU). METHODS: A retrospective sub-analysis of the Global Registry for Endovascular Aortic Treatment including patients treated for abdominal aortic aneurysms with the GORE EXCLUDER AAA Endoprosthesis (W.L. Gore & Associates, Inc, Flagstaff, Arizona) was performed. A "challenging neck" was defined as those treated outside the IFU with an aortic neck length <15 mm and/or aortic neck angle >60°. Cox proportional analyses were used to test for time-to-event differences between those treated within and outside the IFU while accounting for covariates, specifically proximal neck length and neck angle. The main outcomes assessed were 5-year all-cause mortality, 5-year endoleak development (type I or III), and 5-year device-related reinterventions. FINDINGS: Of the 3,324 patients included in the analysis, 411 (12.4%) had a challenging neck and 2,913 (87.6%) did not. The patients in the challenging neck group were significantly older (74.9 years vs. 73.2 years, p≤0.0001) and had a significantly larger aortic aneurysm diameter at the time of the intervention than those treated within the IFU (61.2 mm vs. 56.4 mm, P< 0.0001), shorter proximal neck length (18 mm vs. 30 mm, P< 0.0001) and larger infrarenal neck angle (60.8° vs. 25.8°, P< 0.0001). In the multivariate analysis, brachial access site and challenging neck were not independent risk factors; increased age was associated with a shorter time to mortality (hazard ratio 1.051, 95% confidence interval 1.039-1.062, P< 0.0001), as was the use of tobacco (hazard ratio 1.329, 95% confidence interval 1.124-1.571, P= 0.0009). The 5-year all-cause mortality (36.2% vs. 27.5%, P= 0.002) and aorta-related mortality (3.8% vs. 1.1%, P= 0.002) were significantly higher in the challenging neck group. The risk of death within 5 years also increased significantly at 1.1% per millimetre increase in the abdominal aortic aneurysm diameter (P= 0.0005). Furthermore, the rates of type Ia endoleak development (7% vs. 1.2%, P< 0.001) and requirement for reintervention (13.3% vs. 9.7%, P< 0.001) were higher in those treated outside the IFU (challenging neck group). CONCLUSIONS: Treatment with the Excluder AAA Endograft outside the IFU was associated with higher 5-year mortality values, increased type Ia endoleak development rates, and a greater need for reintervention compared with treatment within the IFU. This reiterates that fenestrated and open treatments should be strongly considered in cases with aortic neck anatomies outside the IFU. Infrarenal endovascular intervention outside the IFU should only be used when there is no alternative, with meticulous procedural planning and intervention to promote satisfactory outcomes.
引用
- Barry IP, Barns M, Verhoeven E, et al. Excluder Stent Graft-Related Outcomes in Patients with Aortic Neck Anatomy Outside of Instructions For Use (IFU) within the Global Registry for Endovascular Aortic Treatment (GREAT): Mid-term Follow-Up Results. Ann Vasc Surg. 2021. PMID: 34182115. doi:10.1016/j.avsg.2021.04.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。